Controlling myopia progressio
Phase 1
Recruiting
- Conditions
- myopia.Myopia
- Registration Number
- IRCT20180216038747N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
myopia -0.50 D to -6.00 D
Astigmatism <= 0.75 D
Exclusion Criteria
myopic children with any ocular diseases such as cataract, glaucoma, uveitis, strabismus, history of trauma, history of any ocular surgery
systemic diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of atropine in myopia progression inhibition in children?
How do 0.01% and 0.02% atropine concentrations compare to standard-of-care myopia treatments in efficacy and safety?
Which ocular biomarkers predict response to atropine treatment in pediatric myopia management?
What are the potential adverse events of low-dose atropine therapy in 6-15 year old myopia patients and their management strategies?
Are there combination therapies or competitor drugs that enhance myopia progression control when used with atropine?